ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 897,37
-0,12%
Dow Jones
44 850,35
0,31%
DAX
21 430,58
0,71%
Brent Oil
76,61
0,45%
Bitcoin
101 243,10
-0,89%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Savara Inc (SVRA) Cours

Savara Inc

Savara Inc (SVRA)

NASDAQ
2,72
0,04
(1,49%)
À la fermeture: 29 Janvier 10:00PM
Retardé de 15 minutes
2,72
0,00
( 0,00% )
Après les heures de négociation: 10:00PM
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
2,72
Prix Achat
2,70
Prix Vente
2,75
Volume échangé
563 040
2,61 Fourchette du Jour 2,745
2,60 Plage de 52 semaines 5,70
Cap du marché
466,804M
Clôture Veille
2,68
Ouverture
2,68
Dernière Transaction
50
@
2.75
Dernière heure de transaction
22:35:06
Volume financier
US$ 1 513 686
VWAP
2,6884
Volume moyen (3 m)
1 477 988
Actions en circulation
171 618 944
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-8,53
Bénéfice par action (BPA)
-0,32
Chiffre d'affairess
-
Bénéfice net
-54,7M

À propos de Savara Inc

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP... Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
savarapharma.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Savara Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker SVRA. Le dernier cours de clôture d'Savara était de US$2,68. Au cours de la dernière année, les actions de Savara ont été négociées dans une fourchette de prix de US$ 2,60 à US$ 5,70.

Savara compte actuellement 171 618 944 actions en circulation. La capitalisation boursière d'Savara est de US$459,94 million. Savara a un ratio cours/bénéfice (ratio PE) de -8.53.

SVRA Dernières nouvelles

Plus de nouvelles

Form 8-K - Current report

23 Janvier 2025
Edgar (US Regulatory)

Form 8-K - Current report

13 Janvier 2025
Edgar (US Regulatory)

Savara Announces New Employment Inducement Grant

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On December 20...

23 Décembre 2024
Business Wire

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

-- Company Expects to Complete BLA Submission by End of 1Q 2025 -- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases...

18 Décembre 2024
Business Wire

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company will present and host 1x1 meetings at...

17 Décembre 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

17 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

17 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

17 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

16 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

16 Décembre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.24-8.108108108112.962.962.6415228132.76170111CS
4-0.39-12.5401929263.113.1552.610786382.87203557CS
12-0.98-26.48648648653.74.2952.614779883.240213CS
26-1.72-38.73873873874.444.742.612694623.66865106CS
52-2.08-43.33333333334.85.72.612797144.07359951CS
1561.56134.4827586211.165.71.026468263.7517103CS
260-0.41-13.09904153353.135.70.99527642682.8206307CS

SVRA - Frequently Asked Questions (FAQ)

What is the current Savara share price?
The current share price of Savara is US$ 2,72
How many Savara shares are in issue?
Savara has 171 618 944 shares in issue
What is the market cap of Savara?
The market capitalisation of Savara is USD 459,94M
What is the 1 year trading range for Savara share price?
Savara has traded in the range of US$ 2,60 to US$ 5,70 during the past year
What is the PE ratio of Savara?
The price to earnings ratio of Savara is -8,53
What is the reporting currency for Savara?
Savara reports financial results in USD
What is the latest annual profit for Savara?
The latest annual profit of Savara is USD -54,7M
What is the registered address of Savara?
The registered address for Savara is CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Savara website address?
The website address for Savara is savarapharma.com
Which industry sector does Savara operate in?
Savara operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
SXTP60 Degrees Pharmaceuticals Inc
US$ 1,09
(41,41%)
5,2M
LGCLLucas GC Ltd
US$ 0,75
(31,12%)
825,04k
FFIEFaraday Future Intelligent Electric Inc
US$ 1,74
(28,89%)
3,82M
PWMPrestige Wealth Inc
US$ 1,37
(28,04%)
366,05k
MFImF International Ltd
US$ 0,9995
(18,40%)
2,22M
WBUYWeBuy Global Ltd
US$ 0,082
(-33,60%)
3,55M
EYENEyenovia Inc
US$ 0,042
(-26,32%)
5,35M
MANHManhattan Associates Inc
US$ 223,00
(-24,43%)
74,81k
HAOHaoxi Health Technology Ltd
US$ 2,8099
(-24,06%)
1,72M
MGOLMGO Global Inc
US$ 0,127
(-23,63%)
13,24M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,0455
(-21,28%)
31,3M
MGOLMGO Global Inc
US$ 0,127
(-23,63%)
13,24M
RIMEAlgorhythm Holdings Inc
US$ 0,0293
(-5,18%)
12,19M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,49
(6,50%)
10,77M
NVDANVIDIA Corporation
US$ 127,84
(-0,89%)
7,96M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
SVRA
Savara
BIT
CY4
Cy4gate
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés